All News

Wonderful overview of myositis autoantibodies to reference from the Rheum Secrets & Pearls session by Dr. @JKolfenbach & Dr. John Stone at #ACR21 that can be accessed on-demand now! @RheumNow https://t.co/H6N02MzFSu
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR21 #Abstr1423 Munroe & James developed a novel #Lupus Classification Risk Immune Index using either 9 or 32 soluble mediators from sera. This index could predict transition to meeting classification criteria (with or without autoantibodies) @RheumNow https://t.co/Kr9fWaoW1L https://t.co/8wkgrzeRnt

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Spanish study finds OP is more frequent in male PsA pts, assoc'd w/age independent of dz hx. Femoral OP more frequent in pts w/ axial involvement, HTN, heart ischemic disease & vitamin D deficiency. Abs 1325 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/A3v6ZHZnN8 https://t.co/2jfAOSuLtK

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
We @HSpecialSurgery previously demonstrated improved fetal mortality in #lupus in @AnnalsofIM Racial disparities persist ~61K #lupus pregnancies - 10 yr US national data #abst1034 at #ACR21 more reduction in Asians and Hispanics than African Americans @RheumNow https://t.co/KeO0FdMB7f
Bella Mehta bella_mehta ( View Tweet)
Abst1314 #acr21 @RheumNow factors associated w/ Acute anterior uveitis in AxSpA: -history of AAU -male gender - presence of extraspinal involvement -concomitant cs-DMARD usage -BASDAI scores ASDAS-CRP, and PGA of disease activity. https://t.co/4YA8dSJzy3
Olga Petryna DrPetryna ( View Tweet)
Raised BMI is related to poorer outcomes to biologics in PsA. The mean change in outcome measures (cDAPSA, RAPID3, PsAID) was lowest among obese patients . This was observed primarily among TNFi initiators vs to OSM or IL17i @RheumNow #ACR21 Abstr#1327 https://t.co/pm7PPp9UH4 https://t.co/j5GWpCBD2d

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Real-world PsA study: MDA assoc'd w/ higher probability of achieving clinically meaningful improvements in dz activity & PROMs. MDA pts more likely w/ b/tsDMARDs, but found in less than 25% of pts in COREVITAS cohort. Abs 1344 #ACR21 #RheumNow @RheumNow https://t.co/RrAfXvn4kf https://t.co/TjPCwzYfZK

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
How does @US_FDA see Tyk2 inh: part of or separate to JAKi class? “I don’t think I’m in a position to make a call on this at this meeting, but certainly Tyk2 is a JAK” Tantalising end to a great session at #ACR21. Feels like the audience could have questions for days. @RheumNow

David Liew drdavidliew ( View Tweet)

#ACR21 plenary#1424. JUNIPERA study for Secukinumab for ERA, JPsA ⭐️Time to disease flare longer in SEC vs PBO ⭐️Sustained improvement up to wk 104 ▶️Rapid decrease of JADAS-27 in initial open-label portion of study https://t.co/m5bl9Ho163 @Rheumnow https://t.co/wnEdxeYfjh

Links:

Eric Dein ericdeinmd ( View Tweet)
Network meta-analysis assessed comparative risk of respiratory tract infection (RTI) with different b/ts DMARD in PsA ⭐️Abatacept 🔽likelihood RTIs compared ADM/ apremilast/ CTZ/ GOL/TOF ⭐️Apremilast 🔼likelihood RTIs compared INX /secukinumab Abst # 1359 #ACR21 @RheumNow

swethaann23 swethaann23 ( View Tweet)

Abst1305 #acr21 @RheumNow undiagnosed depression in AxSpA: 9.9% pts w/abnormal HADs-D scores,23.9% moderate to severe PHQ-9 scores. F had higher mean HADs-D scores than M, w/abnormal scores in 19% of F & 6% M. significantly worse BASDAI&AQoL scores in axSpA pts w/abnormal HADs-D https://t.co/sPkGPcITCs
Olga Petryna DrPetryna ( View Tweet)
Knee OA novel measure of structure and function - Quantitative radiographic OA scores (QROS) software that measures medial minimum joint space width (mJSW) and other measures in the tibiofemoral compartment predicts time to TKA. Model well calibrated @rheumnow #ACR21 #abst1051 https://t.co/9LKlb7bZO0
Bella Mehta bella_mehta ( View Tweet)
Characteristics of #uveitis w/axSpA seen in patients of this study: 👁‍🗨14.6%➡uveitis 👁‍🗨All acute, anterior & 93% unilateral 👁‍🗨Delay in dx & ⬆ HLAB27+ No diff. in TNFi use Consistent fact: Uveitis is the ⬆ common extra-articular manifestation in axSPA @RheumNow #ACR21 abs1324 https://t.co/6qC8RxxBrM
sheila RHEUMarampa ( View Tweet)
Study comparing TNFi vs SEC in PsA pts w/ active US confirmed enthesitis finds superiority of TNFi (ADA, CTZ, ETN) in regards to active entheseal disease. Abs 1356 #ACR21 #RheumNow @RheumNow https://t.co/BvZZsTP3Ta https://t.co/G5cWrQgqDC

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
#ACR21 Abs#1425. AURORA2 - voclosporin for LN extension ⭐️216/357 pts continued into 2-yr study ⭐️Mean UPCR at month 30: 0.58 in VOC vs 1.3 control. eGFR ⬇️ in VOC, remains stable ⭐️No new AEs @Rheumnow https://t.co/m5bl9Ho163 https://t.co/VVGOCd9vmC

Links:

Eric Dein ericdeinmd ( View Tweet)
What better than a tweet on a #ACR21 study of tweets! 😂 Using Twitter Firehose data stream - yes we should do a study just during the ACR week...! Fake tweets exists but low in the rheumatology community! @rheumnow #abst1068 Paper - https://t.co/ekguL5qXen https://t.co/rfy7vZlXOn

Links:

Bella Mehta bella_mehta ( View Tweet)
Abst1356 #acr21 @RheumNow TNFi vs SEC in active US confirmed enthesitis: mean ActiveMASEI score ⬇️ 4.37 w/TNFi vs 2.22 secukinumab (p = 0.030). Secucinumab leads in regards to the PASI & DLQI score with Sec vs TNFi ( 3.44 vs 1.03 p = 0.001 & 5.57 vs 1.35 p = 0.005 respectively https://t.co/fGTxzvGY99
Olga Petryna DrPetryna ( View Tweet)
FDA Safety Update - Questions for Dr. Nikolov, Habal, Golding, Rajpal - Do we need post marketing RCTs BARI and UPA: one in prog for BARI, not for UPA - 1133, why high CI of 1.8? Based on stricter margins based on prior studies with diabetes - Are Tyk2 a worry? to early -#ACR21

Dr. John Cush RheumNow ( View Tweet)

FDA Safety Update - Questions for Dr. Nikolov, Habal, Golding, Rajpal - Bari OK in COVID but now CV risk: theres a limit (14d) for Bari in COVID - CV Risk applied to all JAKi - largely because all have same indication, same populations at risk #ACR21

Dr. John Cush RheumNow ( View Tweet)

FDA update - the safety of XIAFLEX injections (collagenase for Dupytrens) under review #ACR21 https://t.co/KOP3P8ASqN
Dr. John Cush RheumNow ( View Tweet)
×